The impact of intravenous thrombolysis in acute ischemic stroke in National Medical College, Kolkata: initial experience

Authors

  • Saikat Ghosh Department of Neurology, NRS Medical College, Kolkata, West Bengal, India
  • Manoj Kr. Mahata Department of Neurosurgery, Hyogo College of Medicine, Japan
  • Sarbajit Das Department of Neurology, Calcutta National Medical College, Kolkata, West Bengal, India
  • K. C. Ghosh Department of Neurology, Calcutta National Medical College, Kolkata, West Bengal, India
  • R. Bhattacharya Department of Neurology, Calcutta National Medical College, Kolkata, West Bengal, India
  • G. P. Mondal Department of Neurology, Calcutta National Medical College, Kolkata, West Bengal, India
  • Sumit Deb Department of Neurology, Calcutta National Medical College, Kolkata, West Bengal, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20195240

Keywords:

Atherothrombosis, Cardioembolic, Dyslipidaemia, Ischemic stroke, Thrombolysis

Abstract

Background: Acute ischemic stroke is a potentially treatable condition, if left untreated, lead to mortality and morbidity. This study was conducted to study clinical profile of patients with acute ischemic stroke receiving intravenous thrombolysis (r-TPA-alteplase) and to measure the outcome of thrombolysis.

Methods: Retrospective observational study of 54 patients who underwent thrombolysis for acute ischemic stroke at National Medical College, Kolkata over a period of one year.

Results: There was statistically significant improvement in NIHSS (p value-0.000) after intravenous thrombolysis.

Conclusions: IV thrombolysis is feasible for AIS in governmental hospital in India.

References

Ninds T. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-7.

Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29.

Belkouch A, Jidane S, Chouaib N, Elbouti A, Nebhani T, Sirbou R, et al. Thrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital. Pan African Med J. 2015;21(1).

Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82.

Rha JH, Shrivastava VP, Wang Y, Lee KE, Ahmed N, Bluhmki E, et al. Thrombolysis for acute ischaemic stroke with alteplase in an A sian population: results of the multicentre, multinational safe implementation of thrombolysis in stroke‐non‐European Union World (SITS‐NEW). Inter J Stroke. 2014 Oct;9:93-101.

Wasay M, Khatri IA, Kaul S. Stroke in South Asian countries. Nat Rev Neurol. 2014 Mar;10(3):135-43.

Nayak SD, Nair M, Radhakrishnan K, Sarma PS. Ischaemic stroke in the young adult: clinical features, risk factors and outcome. Natl Med J Ind. 1997 May 1;10(3):107-12.

Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010 Sep 1;41(9):1984-9.

Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat. 2011;2011:686-797.

Pandian JD, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Inter J Stroke. 2007 Feb;2(1):17-26.

Downloads

Published

2019-11-25

Issue

Section

Original Research Articles